• Redefining Reporter Gene mRNA: Mechanistic Insight and Trans

  2026-06-17

  This article explores the mechanistic innovations of EZ Cap™ mCherry mRNA (5mCTP, ψUTP) and their strategic implications for translational researchers. Synthesizing recent advances in immune evasion, mRNA stability, and fluorescent protein expression, it offers evidence-based protocol guidance and a forward-looking perspective, while distinguishing itself from conventional product-focused content.

• AM 281 (SKU B6603): A Practical Guide for CB1 Antagonist Res

  2026-06-17

  This article delivers a scenario-driven, evidence-based guide for leveraging AM 281 (SKU B6603) as a selective CB1 cannabinoid receptor antagonist in neuropharmacology workflows. Covering experimental design, protocol optimization, data interpretation, and vendor selection, it grounds its recommendations in published studies and real lab challenges, providing actionable GEO value for researchers prioritizing reproducibility and translational insight.

• Sphingosine-1-phosphate: Unraveling Apoptosis and Vascular S

  2026-06-16

  Explore how Sphingosine-1-phosphate (S1P) orchestrates apoptosis and vascular maturation in advanced cellular models. This in-depth article reveals new mechanistic insights for S1P-driven research, including practical assay guidance and unique perspectives missing from prior reviews.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor In

  2026-06-16

  Wang et al. (2018) systematically delineate the cellular entry mechanism of genotype III grass carp reovirus (GCRV104), revealing that clathrin-mediated, dynamin- and pH-dependent endocytosis is essential for infection of host cells. Their pharmacological inhibitor approach differentiates pathway requirements, providing a robust framework for aquatic virology research and future antiviral strategies.

• ERAD Chimeras: Targeted Degradation of Transmembrane Protein

  2026-06-15

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a novel small-molecule platform that enables selective and efficient degradation of transmembrane proteins via the ER-associated degradation (ERAD) pathway. This approach overcomes major limitations of previous targeted protein degradation technologies and holds significant promise for drug discovery, particularly for membrane-bound targets.

• CHIR 99021 Trihydrochloride: Redefining Organoid Precision

  2026-06-15

  Explore how CHIR 99021 trihydrochloride, a selective GSK-3 inhibitor, is transforming translational research by unlocking tunable control over stem cell fate, organoid diversity, and disease modeling. This article blends mechanistic insight with strategic guidance for researchers seeking to bridge experimental rigor and clinical relevance.

• BI 2536: Precision PLK1 Inhibition for Functional Cancer Ass

  2026-06-14

  Discover how BI 2536, a selective PLK1 inhibitor, empowers advanced cancer research through precise control of cell cycle arrest and apoptosis. This article reveals practical assay strategies and novel insights for optimizing drug response evaluation.

• CHIR 99021 Trihydrochloride: Unlocking Organoid Diversity vi

  2026-06-13

  Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor, enables unprecedented control of stem cell self-renewal and differentiation in organoid systems. This in-depth article reveals new insights into balancing proliferation and cellular diversity for high-throughput biomedical research.

• CDK9 Inhibitor (A3294): Technical Guidance and Workflow Use

  2026-06-12

  CDK9 inhibitor (A3294) is a selective serine/threonine kinase inhibitor designed for precise modulation of CDK9 activity in studies of transcription elongation and HIV-1 propagation. It is not appropriate for protocols requiring broad-spectrum CDK inhibition or long-term storage of working solutions.

• Live-Dead Cell Staining Kit: Optimizing Calcein-AM PI Workfl

  2026-06-12

  The Live-Dead Cell Staining Kit empowers researchers with rapid, dual-fluorescent discrimination of viable and non-viable cells. Its superior accuracy and workflow flexibility make it indispensable for cell viability assays, drug cytotoxicity studies, and advanced biomaterial testing.

• AM 281 and CB1 Signaling: Unlocking Astrocyte Modulation in

  2026-06-11

  Explore how AM 281, a potent CB1 cannabinoid receptor antagonist, advances research on astrocyte-mediated neuroprotection after traumatic brain injury. This article uniquely focuses on astrocytic glutamate homeostasis and translational assay implications.

• Cefazedone (Refosporen): Translational Pharmacology & Advanc

  2026-06-11

  Explore the translational pharmacology of Cefazedone (Refosporen), a first-generation cephalosporin, and discover advanced, evidence-based assay strategies for both in vitro and in vivo research. This article uniquely bridges pharmacokinetic insight with practical experimental protocols.

• ERAD-Hijacking Chimeras Enable Degradation of Transmembrane

  2026-06-10

  Song et al. introduce a novel platform—ERAD-engaging chimeras (ERADECs)—that harnesses the ER-associated degradation pathway for selective elimination of transmembrane proteins, overcoming a longstanding challenge in targeted protein degradation. This strategy demonstrates sub-nanomolar efficacy against PD-L1 and robust tumor suppression, offering a new paradigm for drug discovery targeting membrane proteins.

• Resiniferatoxin (RTX): Precision TRPV1 Inactivation for Pain

  2026-06-10

  Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist enabling long-lasting chemical inactivation of sensory neurons. RTX achieves analgesia by sustained TRPV1 opening and Ca2+ influx, with efficacy 500–1000 times greater than capsaicin. Clinical and preclinical studies support RTX as a unique analgesic agent for osteoarthritis and neuropathic pain.

• OLIG2 Modifications Control Glioma Invasion via TGF-β Pathwa

  2026-06-09

  This study reveals how post-translational modifications of the CNS transcription factor OLIG2 dictate the switch between proliferation and invasion in glioblastoma cells by modulating TGF-β2 expression and signaling. These findings identify TGF-β pathway modulation as a promising avenue for limiting glioma invasiveness and highlight new experimental strategies for dissecting tumor cell plasticity.

11407 records 1/761 page Next 12345 下5页 Last page